tiprankstipranks
Trending News
More News >
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
US Market

Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

Compare
174 Followers
See the Price Targets and Ratings of:

ENTA Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Enanta
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ENTA Stock 12 Month Forecast

Average Price Target

$17.00
▲(139.10%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Enanta Pharmaceuticals in the last 3 months. The average price target is $17.00 with a high forecast of $24.00 and a low forecast of $7.00. The average price target represents a 139.10% change from the last price of $7.11.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","25":"$25","9.25":"$9.25","14.5":"$14.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.25,14.5,19.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.29,7.6523076923076925,9.014615384615386,10.376923076923077,11.739230769230769,13.101538461538462,14.463846153846156,15.826153846153847,17.18846153846154,18.55076923076923,19.913076923076925,21.275384615384617,22.63769230769231,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.29,7.113846153846154,7.937692307692307,8.76153846153846,9.585384615384616,10.40923076923077,11.233076923076922,12.056923076923077,12.880769230769232,13.704615384615385,14.528461538461539,15.352307692307694,16.176153846153845,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.29,6.344615384615385,6.399230769230769,6.453846153846154,6.508461538461538,6.563076923076923,6.617692307692308,6.672307692307692,6.726923076923077,6.781538461538462,6.836153846153846,6.890769230769231,6.945384615384615,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.08,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.47,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$24.00Average Price Target$17.00Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ENTA
TipRanks AITipRanks
Not Ranked
TipRanks
$7.5
Hold
5.49%
Upside
Reiterated
06/05/25
Enanta Pharmaceuticals scores moderately due to strong technical momentum, despite facing significant financial and valuation challenges. The bullish momentum is counterbalanced by the company's negative financial performance and valuation metrics.
Citizens JMP Analyst forecast on ENTA
Roy BuchananCitizens JMP
Citizens JMP
$23$24
Buy
237.55%
Upside
Reiterated
06/03/25
Enanta price target raised to $24 from $23 at Citizens JMPEnanta price target raised to $24 from $23 at Citizens JMP
Evercore ISI Analyst forecast on ENTA
Liisa BaykoEvercore ISI
Evercore ISI
$20
Buy
181.29%
Upside
Reiterated
05/13/25
Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)
Leerink Partners Analyst forecast on ENTA
Roanna RuizLeerink Partners
Leerink Partners
$8$7
Hold
-1.55%
Downside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (NASDAQ: ENTA) and Karyopharm Therapeutics (NASDAQ: KPTI)
H.C. Wainwright Analyst forecast on ENTA
Ed ArceH.C. Wainwright
H.C. Wainwright
$18
Buy
153.16%
Upside
Reiterated
02/10/25
Enanta Pharmaceuticals: Buy Rating Driven by Promising RSV Developments and Strategic Plans
J.P. Morgan Analyst forecast on ENTA
Eric JosephJ.P. Morgan
J.P. Morgan
$9$5
Sell
-29.68%
Downside
Reiterated
02/10/25
Enanta Pharmaceuticals (ENTA) Receives a Sell from J.P. Morgan
Oppenheimer Analyst forecast on ENTA
Jay OlsonOppenheimer
Oppenheimer
$14
Hold
96.91%
Upside
Reiterated
12/10/24
Enanta Pharmaceuticals (ENTA) Gets a Hold from Oppenheimer
Robert W. Baird Analyst forecast on ENTA
Brian SkorneyRobert W. Baird
Robert W. Baird
$26$20
Buy
181.29%
Upside
Reiterated
11/26/24
Enanta price target lowered to $20 from $26 at BairdEnanta price target lowered to $20 from $26 at Baird
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ENTA
TipRanks AITipRanks
Not Ranked
TipRanks
$7.5
Hold
5.49%
Upside
Reiterated
06/05/25
Enanta Pharmaceuticals scores moderately due to strong technical momentum, despite facing significant financial and valuation challenges. The bullish momentum is counterbalanced by the company's negative financial performance and valuation metrics.
Citizens JMP Analyst forecast on ENTA
Roy BuchananCitizens JMP
Citizens JMP
$23$24
Buy
237.55%
Upside
Reiterated
06/03/25
Enanta price target raised to $24 from $23 at Citizens JMPEnanta price target raised to $24 from $23 at Citizens JMP
Evercore ISI Analyst forecast on ENTA
Liisa BaykoEvercore ISI
Evercore ISI
$20
Buy
181.29%
Upside
Reiterated
05/13/25
Evercore ISI Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA)
Leerink Partners Analyst forecast on ENTA
Roanna RuizLeerink Partners
Leerink Partners
$8$7
Hold
-1.55%
Downside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (NASDAQ: ENTA) and Karyopharm Therapeutics (NASDAQ: KPTI)
H.C. Wainwright Analyst forecast on ENTA
Ed ArceH.C. Wainwright
H.C. Wainwright
$18
Buy
153.16%
Upside
Reiterated
02/10/25
Enanta Pharmaceuticals: Buy Rating Driven by Promising RSV Developments and Strategic Plans
J.P. Morgan Analyst forecast on ENTA
Eric JosephJ.P. Morgan
J.P. Morgan
$9$5
Sell
-29.68%
Downside
Reiterated
02/10/25
Enanta Pharmaceuticals (ENTA) Receives a Sell from J.P. Morgan
Oppenheimer Analyst forecast on ENTA
Jay OlsonOppenheimer
Oppenheimer
$14
Hold
96.91%
Upside
Reiterated
12/10/24
Enanta Pharmaceuticals (ENTA) Gets a Hold from Oppenheimer
Robert W. Baird Analyst forecast on ENTA
Brian SkorneyRobert W. Baird
Robert W. Baird
$26$20
Buy
181.29%
Upside
Reiterated
11/26/24
Enanta price target lowered to $20 from $26 at BairdEnanta price target lowered to $20 from $26 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enanta Pharmaceuticals

1 Month
xxx
Success Rate
14/21 ratings generated profit
67%
Average Return
+8.25%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +8.25% per trade.
3 Months
xxx
Success Rate
12/22 ratings generated profit
55%
Average Return
+4.76%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +4.76% per trade.
1 Year
Liisa BaykoEvercore ISI
Success Rate
11/21 ratings generated profit
52%
Average Return
+6.60%
reiterated a buy rating 25 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +6.60% per trade.
2 Years
xxx
Success Rate
13/21 ratings generated profit
62%
Average Return
+7.54%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 61.90% of your transactions generating a profit, with an average return of +7.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ENTA Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
May 25
Jun 25
Strong Buy
8
6
7
5
6
Buy
0
0
0
0
0
Hold
4
5
4
3
2
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
13
12
12
9
9
In the current month, ENTA has received 6 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. ENTA average Analyst price target in the past 3 months is 17.00.
Each month's total comprises the sum of three months' worth of ratings.

ENTA Financial Forecast

ENTA Earnings Forecast

Next quarter’s earnings estimate for ENTA is -$0.53 with a range of -$1.68 to $0.61. The previous quarter’s EPS was -$1.06. ENTA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ENTA has Outperformed its overall industry.
Next quarter’s earnings estimate for ENTA is -$0.53 with a range of -$1.68 to $0.61. The previous quarter’s EPS was -$1.06. ENTA beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ENTA has Outperformed its overall industry.

ENTA Sales Forecast

Next quarter’s sales forecast for ENTA is $16.17M with a range of $15.10M to $17.62M. The previous quarter’s sales results were $14.93M. ENTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ENTA has Outperformed its overall industry.
Next quarter’s sales forecast for ENTA is $16.17M with a range of $15.10M to $17.62M. The previous quarter’s sales results were $14.93M. ENTA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year ENTA has Outperformed its overall industry.

ENTA Stock Forecast FAQ

What is ENTA’s average 12-month price target, according to analysts?
Based on analyst ratings, Enanta Pharmaceuticals’s 12-month average price target is 17.00.
    What is ENTA’s upside potential, based on the analysts’ average price target?
    Enanta Pharmaceuticals has 139.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ENTA a Buy, Sell or Hold?
          Enanta Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Enanta Pharmaceuticals’s price target?
            The average price target for Enanta Pharmaceuticals is 17.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $24.00 ,the lowest forecast is $7.00. The average price target represents 139.10% Increase from the current price of $7.11.
              What do analysts say about Enanta Pharmaceuticals?
              Enanta Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of ENTA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis